Rhytec, Inc. announced today that the Food and Drug Administration cleared Portrait(R) Plasma Skin Regeneration (Portrait(R) PSR3) system, for use in treating non-facial rhytides (wrinkles). Portrait(R) PSR3 was cleared in 2005 for the treatment of wrinkles of the face and in 2003 for the treatment of facial and non-facial areas for superficial skin lesions, actinic keratosis, seborrhoeic keratosis and viral papillomata.

This new FDA clearance, coupled with the previous clearances, makes Portrait(R) the only plasma skin regeneration technology available for patients seeking cosmetic improvement for individual or simultaneous treatment of wrinkles, benign skin lesions and actinic (sun) damage of the whole body.

Mark Goble, MD, Chief Executive Officer and founder of Rhytec, Inc. commented, \"Our Portrait Plasma Skin Regeneration system is a uniquely versatile technology that can be optimized to meet patient expectations in the treatment of a variety of cosmetic indications. The broadening of our FDA clearance to encompass treatment of non-facial areas of the body represents an important step in realizing the potential of our technology and creating value for our customers and clinical results for patients.\"

About Portrait(R)

Portrait(R) delivers nitrogen plasma (a highly energized gas) energy, which works both at and below the surface of the skin to modify the skin\'s architecture and generate new collagen. The skin\'s outer layers remain intact and act as a protective cover until new skin regenerates. Once this happens, the old skin peels away taking with it all the signs of years of exposure to the sun, including brown sun spots and actinic keratoses (rough-textured patches or lesions that form on the outermost layer of the skin), fine lines and deep wrinkles. Additionally Portrait(R) has profound sustainable cosmetic effects on skin tone, texture and laxity. All of these conditions are treated simultaneously -- a unique and significant advantage that distinguishes Portrait(R) from other cosmetic skin treatments. There is no evidence of scarring or hypopigmentation in clinical studies to date.

About Rhytec

Rhytec develops innovative technologies based on sound scientific and clinical research for the dermatological, plastic and cosmetic surgery markets. Plasma energy stimulates a true skin regenerative process that is supported by 30 completed and ongoing clinical trials. Founded in 2004, Rhytec works with leading plastic surgeons, dermatologists and cosmetic physicians to develop new technologies that enhance the skin\'s appearance and function in order to improve the quality of life for patients seeking treatment. Rhytec, Inc. is privately held, based in Waltham, MA (US) and is a subsidiary of Rhytec, Ltd. in Berkshire (UK).